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Abstract: Magnetically responsive microbubbles (MagMBs), consisting of an oxygen gas core 
and a phospholipid coating functionalised with Rose Bengal (RB) and/or  5-fluorouracil (5-FU), 
were assessed as a delivery vehicle for the targeted treatment of pancreatic cancer using 
combined antimetabolite and sonodynamic therapy (SDT). MagMBs delivering the combined 5-
FU/SDT treatment produced a reduction in cell viability of over 50% when tested against a panel 
of four pancreatic cancer cell lines in vitro. Intravenous administration of the MagMBs to mice 
bearing orthotopic human xenograft BxPC-3 tumours yielded a 48.3% reduction in tumour 
volume relative to an untreated control group (p<0.05) when the tumour was exposed to both 
external magnetic and ultrasound fields during administration of the MagMBs. In contrast, 
application of an external ultrasound field alone resulted in a 27% reduction in tumour volume. 
In addition, activated caspase and BAX protein levels were both observed to be significantly 
elevated in tumours harvested from animals treated with the MagMBs in the presence of 
magnetic and ultrasonic fields when compared to expression of those proteins in tumours from 
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either the control or ultrasound field only groups (p<0.05). These results suggest MagMBs have 
considerable potential as a platform to enable the targeted delivery of combined sonodynamic / 
antimetabolite therapy in pancreatic cancer.  
Key words: Microbubbles, magnetic targeting, drug delivery, hypoxia, 5-fluoruracil, Rose 
Bengal, sonodynamic therapy, antimetabolite therapy, pancreatic cancer. 
 
1.0 Introduction: Pancreatic cancer has the lowest survival rate among the 21 most common 
forms of cancer with only 3% of patients surviving five years after their initial diagnosis [1]. 
Whilst many other forms of cancer have seen survival rates increase significantly over the past 
four decades, the survival rate for pancreatic cancer has remained unchanged. Late 
presentation of patients due to the vague symptoms associated with the disease means only ~ 
20% are eligible for potentially curative resection at the time of initial diagnosis [2]. Of the 
remaining ~ 80% of patients, ~50% present with metastatic disease and ~30% with locally 
advanced or borderline resectable pancreatic cancer (LAPC or BRPC) [3]. While earlier 
diagnosis and better awareness are key components of any future strategy to improve survival 
rates, there is also an urgent need for improved therapies. Several studies have investigated the 
potential of neo-adjuvant chemo- and / or radio-therapy to downstage tumours and increase the 
number of patients eligible for resection [3,4,5]. Unfortunately, such treatments are often 
associated with significant off-target effects due to the non-specific nature of the chemotherapy 
regimen. Therefore, the development of targeted treatments that reduce side-effects related to 
systemic chemotherapy have enormous potential as neo-adjuvant and palliative pancreatic 
cancer treatments by reducing tumour burden to either enable surgery or to provide symptom 
relief. 
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In a previous study, we demonstrated the utility of ultrasound responsive microbubbles 
(MBs) for delivery of drug payloads and encapsulated oxygen gas to pancreatic tumours [6]. 
MBs are lipid or polymer stabilised gas filled particles approved for use as contrast agents in 
diagnostic ultrasound [7]. At low ultrasound pressures, MBs oscillate in a relatively symmetric 
manner resulting in acoustic backscatter that enhances the quality of the diagnostic image [8]. 
Exposure of cells to low intensity ultrasound can also facilitate a phenomenon known as 
sonoporation which causes a transient ‘poration’ of cellular plasma membranes and the 
phenomenon is enhanced in the presence of exogenously-added MBs. Such an approach has 
been exploited to enhance the efficacy of gemcitabine therapy in pancreatic cancer patients [9-
10]. In contrast, at higher acoustic pressures, collapse of the MB leads to rupture and release of 
the shell fragments at the target site [11]. This feature has been exploited by several groups 
investigating the potential of MBs as targeted delivery vehicles [12,13]. In our previous work, we 
attached the antimetabolite drug 5-fluouracil (5-FU) and the sonosensitiser Rose Bengal (RB) to 
the shell of oxygen-loaded lipid stabilised MBs for the combined antimetabolite and 
sonodynamic therapy (SDT) treatment of pancreatic cancer [6]. Significant reductions in the 
viability of three pancreatic cancer cell lines (BxPC3, MiaPaCa-2 and Panc-01) and inhibition of 
the growth of ectopic pancreatic BxPC-3 tumours were observed for the combined treatment 
when compared to either treatment alone. Antimetabolite therapy is an established treatment 
protocol for pancreatic cancer with 5-FU and gemcitabine among the most commonly used 
antimetabolite drugs [14]. In contrast, SDT is an emerging anti-cancer treatment that involves 
the activation of an otherwise inactive sensitiser drug using low-intensity ultrasound [15]. The 
combination of sensitiser and ultrasound, in the presence of molecular oxygen, generates 
cytotoxic levels of reactive oxygen species (ROS) causing cell death via oxidative stress [16]. 
As oxygen is a key substrate for the generation of ROS in SDT, and since pancreatic 
adenocarcinoma is characterised as extremely hypoxic, providing oxygen during SDT can 
improve the ROS yield and enhance the therapeutic outcome [17]. While our oxygen carrying 
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MBs have shown great promise as a platform for targeted oxygen delivery and enhanced 5-FU / 
SDT treatment of pancreatic cancer, there remains a need to demonstrate the effectiveness of 
this method in an orthotopic tumour model following intravenous injection of the MB suspension. 
To this end, we have reasoned that an additional layer of targeting may be required to help 
retain MBs in the tumour vasculature after injection and enhance the quantity of MBs destroyed 
at the target site by ultrasound exposure. The incorporation of magnetic nanoparticles within the 
MB shell is one approach that has been explored to improve the targeting capability of MBs. 
[18]. Previous work in our laboratory has demonstrated that externally applied magnetic fields 
may be used to enhance the retention of magnetically-responsive microbubbles at a target site 
in an ex vivo model under physiologically-relevant flow rates [19]. In this manuscript, we assess 
the ability of oxygen loaded magnetic MBs with 5-FU and Rose Bengal attached to their surface, 
as a targeted treatment for orthotopic human pancreatic BxPC-3 tumours in SCID mice. The 
benefit afforded by incorporating magnetic targeting into our delivery platform is demonstrated 
by studies in a flow-phantom and by therapeutic efficacy studies in vivo. 
2.0 Materials and Methods  
2.1 Reagents and Equipment: 1,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol) -2000] (DSPE-
PEG(2000)) and DSPE-PEG(2000)-biotin were purchased from Avanti Polar Lipids (Alabaster, 
Alabama, USA). Oxygen gas was purchased from BOC Industrial Gases UK and 
perfluorobutane (PFB) was purchased from Apollo Scientific Ltd. Phosphate Buffered Saline 
(PBS) was purchased from Gibco, Life Technologies, UK. Glycerol and propylene glycol (1kg, 
hydrolysed) were purchased from Sigma Aldrich (UK). Superparamagnetic iron oxide 
nanoparticles (SPION): fluidMAG-Lipid (50 nm hydrodynamic diameter) were purchased from 
Chemicell (Berlin, Germany). The use of lipid conjugated SPION in this study was preferred 
over the use of previously reported isoparaffin stabilised SPION as the addition of lipids to lipid-
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shelled microbubbles is likely to be less disruptive to the acoustic response of the system 
compared to the addition of isoparaffin [19]. These microbubbles have been extensively 
characterised and successfully used in previous in vivo experiments [20]. The method for 
magnetic microbubble fabrication used in this study has then been adapted for the use of lipid 
conjugated SPION: fluidMAG-Lipid as presented in the following section. MBs were formed 
using a Microson ultrasonic cell disruptor, 100 W, 22.5 kHz, from Misonix Inc. (NY, USA). 
Optical microscope images were obtained using a Leica DM500 optical microscope. MB 
concentration and size were determined using purpose- written MATLAB software (2010B, 
MathWorks, Natick, MA, USA). Rose Bengal sodium salt, NHS-biotin, MTT assay kit, avidin, 
chloroacetic acid, 4-dimethylaminopyridine (DMAP), hydroxybenzotriazole (HOBt), N,N’-
dicyclohexylcarbodiimide (DCC), anhydrous dimethylformamide (DMF), and ethanol were 
purchased from Sigma Aldrich (UK) at the highest grade possible. Biotin, 5-Flurouracil, di(N-
succinimidyl)carbonate and 2-aminoethanol were purchased from Tokyo Chemical Industry UK 
Ltd. Error was expressed as ± SEM (standard error of the mean) and statistical comparisons 
were established using ANOVA and un-paired student’s t-test .  
2.2 Preparation of Avidin functionalised Magnetic Microbubbles (MagPFBMBs): Avidin 
functionalised magnetic MBs were prepared by dissolving DBPC (4.0 mg, 4.43 µmol), DSPE-
PEG(2000) (1.35 mg, 0.481 µmol) and DSPE-PEG(2000)-biotin (1.45 mg, 0.481 µmol) at a 
molar ratio of 82:9:9 in chloroform (274 µL). The chloroform solvent was slowly evaporated by 
heating the lipid solution at 40oC overnight to produce a dried lipid film. The lipid film was 
reconstituted in 2 mL of a PBS (pH 7.4 ± 0.1) : propylene glycol : glycerol (8:1:1 v/v) mixture and 
the contents heated at 80oC under stirring for 30 min in a water bath. FluidMAG-Lipids NPs (150 
µL) were then added to the solution and the mixture was sonicated with a handheld sonicator 
probe for 1.5 min (100 W, 22.5 kHz, power setting 4). The headspace of the glass vial was then 
filled with perfluorobutane gas (PFB) and the gas / liquid interface was sonicated for 20 s (power 
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setting 19), producing PFB-containing magnetic MBs (MagPFBMBs). The vial was immediately 
sealed and placed in an ice bath for 10 min. The MagPFBMB suspension was then centrifuged 
(100 RCF, 5 min) to remove the excess NPs and non-incorporated MB lipids by discarding the 
infranatant. The microbubble concentrate was re-suspended in 2 mL of PBS (pH 7.4 ± 0.1) : 
propylene glycol : glycerol (8:1:1 v/v), avidin in PBS (50 µL, 10 mg/mL) was added to the 
suspension and the contents mixed for 10 min on a rotary shaker. The suspension was 
centrifuged (100 RCF, 5 min) to remove the excess avidin and the PFBMBs were again re-
suspended in 2 mL of PBS (pH 7.4 ± 0.1) : propylene glycol : glycerol (8:1:1 v/v). MagPFBMBs 
were analysed using a Leica DM500 optical microscope to obtain the size distribution and 
concentration. For this, 10 µL of suspension was diluted in 190 µL of PBS and examined using 
a haemocytometer (Bright-Line, Hausser Scientific, Horsham, PA, USA). 30 images were 
obtained with a 40x objective lens and analysed with customised image analysis package in 
MATLAB (2010B, MathWorks, Natick, MA, USA). The iron content in the MagPFBMBs was 
determined by atomic absorption spectroscopy using a Varian fast sequential atomic absorption 
spectrometer. A calibration curve was constructed using known concentrations of Fe(III) in 0.5M 
HCl. Readings were taken at 248.3nm, 0.5nm slit width, 10.0mA lamp current, with the following 
flame settings; flame type: air/acetylene, air flow: 13.50 L/min, acetylene flow: 2.00 L/min, 
burner height: 13.5mm. A 300 µL sample of MagMBs was sonicated to destroy the bubbles and 
dissolved in 0.5M HCl. The amount of Fe(III) present in the sample was calculated by reference 
to the calibration curve and the total iron content determined using a magnetite (Fe3O4) Fe(III) : 
Fe(II) ratio of 2:1. 
2.3 Preparation of MagO2MB-Rose Bengal and MagO2MB-5FU conjugates: The synthesis of 
biotin functionalised Rose Bengal [16] and biotin functionalised 5-FU [6] have been described by 
us in previous communications. Saturated solutions of biotin-RB and biotin 5-FU were prepared 
in a 0.5% (v/v) DMSO : PBS (pH 7.4 ± 0.1) solvent mixture. 100 µL of biotin-5FU and biotin-RB 
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were added to separate samples (2mL each) of MagPFBMBs and allowed to mix for 5 min on a 
rotary shaker. Both samples were centrifuged (100 RCF, 5 min) to remove unbound material 
and PFBMB conjugates were re-suspended in 1 mL of PBS solution (pH 7.4 ± 0.1). This 
conjugation / centrifugation process was repeated three times. The final PFBMB-RB and 
PFBMB-5FU conjugates were transferred to glass vials. MagO2MB-RB and MagO2MB-5FU 
conjugates were obtained by sparging the MagPFBMB-RB and MagPFBMB-5FU with pure O2 
gas for 2 min and sealing the vial via crimping.  A small sample (100 µL) of both the MagO2MB-
RB and MagO2MB-5FU conjugates was retained and the MB number again counted using a 
haemocytometer. The remaining sample was sonicated in an ultrasonic bath for 5 min to burst 
the MBs and the Rose Bengal and 5-FU concentration determined using UV-Vis (ultra violet – 
visible) spectroscopy and HPLC (high performance liquid chromatography) respectively [21]. 
2.4 Retention of MagMBs in a flow cell using an external magnetic field: MagPFBMBs 
without payload were used in this study to reduce wastage of biotin-5FU and biotin-RB. 1 x 107 
MagPFBMBs were placed in a 1 mL syringe, connected to an ibidi µ-Slide VI flow chamber 
using silicone tubing (1.6 mm internal diameter) and placed in a peristaltic syringe pump. A 
single N52 grade NdFeB permanent magnet cube (12.7 mm) with an internal magnetization of 
1.14×106 A/m was positioned 1 mm from the base of the flow chamber. Values for a field of 0.46 
T and gradient of 83.1 T/m inside the flow chamber were calculated using a model described 
and experimentally verified previously [22], whereby the field was determined by breaking the 
magnet into a 3-dimensional lattice of evenly-distributed point moments, and summing the 
contributed dipole field from each moment. The MagPFBMBs were pumped through the flow 
chamber at a rate of 0.6 mL/min. Once the syringe was empty, the magnetic field was removed 
and 1 mL of PBS (pH 7.4 ± 0.1) added to the syringe to flush the flow chamber’s content into a 
clean vial. Collected MBs were counted using the method described above. As a control, the 
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experiment was repeated in the absence of a magnetic field but under otherwise identical 
conditions. The number of MBs collected during the PBS flush was again recorded.    
2.5 In vitro cell viability: Human primary pancreatic adenocarcinoma cell lines Mia PaCa-2 
and Panc-1, were maintained in DMEM medium. The mouse primary pancreatic 
adenocarcinoma T110299 derived from a GEM mouse (KPC and a gift from Prof. J. Siveke, 
Technical University of Munich, Germany), was also maintained in DMEM medium while the 
human primary pancreatic adenocarcinoma cell line BxPc-3 was maintained in RPMI-1640 
medium, all of which were supplemented with 10% (v/v) foetal bovine serum and grown in a 
humidified 5% CO2 atmosphere at 37°C. These cells were plated into the wells of a 96-well 
tissue culture plate at a concentration of 5 × 103 cells per well and incubated for 24 h at 37 °C in 
a humidified 5% CO2 atmosphere. The media was then removed from each well and replaced 
with 100 μL of treatment suspension and 100 μL of fresh mediium. This resulted in a final MB 
count and RB or 5-FU concentration as follows:  MagO2MB-RB: 10
6 MB, [RB] = 5 µM; 
MagO2MB-5FU; 10
7 MB, [5-FU] = 100 µM and combined MagO2MB-RB / MagO2MB-5FU: 10
7 
MB, [RB] = 5 µM, [5-FU] = 100 µM. Where required, individual wells were then placed in direct 
contact with the emitting surface a Sonidel SP100 sonoporator with ultrasound gel used to 
mediate contact. Each well was treated with ultrasound for 30 s, using a frequency of 1 MHz, an 
ultrasound power density of 3.0 W cm− 2 (ISATP; spatial average, temporal peak) corresponding to 
a peak to peak pressure of 0.8 MPa in water and 0.5 MPa inside the well as measured with a 
needle hydrophone (Precision Acoustics, Dorset, UK); and a duty cycle of 50% (pulse frequency 
= 100 Hz). The solution was then removed from the wells and fresh medium added (200 μL). 
Plates were incubated in a humidified 5% CO2 atmosphere at 37 °C for 21 h and cell viability 
determined using an MTT assay [23]. Results were compared with those obtained using 
untreated cells and cells exposed to ultrasound treatment alone. 
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2.6 Treatment of orthotopic BxPC-3 Luc tumours in SCID mice: All animals employed in this 
study were treated humanely and in accordance with licenced procedures under the UK 
Animals (Scientific Procedures) Act 1986. BxPc-3 Luc cells were maintained in RPMI-1640 
medium supplemented with 10% foetal calf serum as described above.  Cells (1 x106) were re-
suspended in 100 µL of Matrigel® and orthotopically implanted into the head of the pancreas of 
female Balb/c SCID (C.B-17/IcrHan®Hsd-Prkdcscid) mice. 19 days after implantation, animals 
were randomly distributed into 3 groups (n=4). Following induction of anaesthesia 
(intraperitoneal injection of Hypnorm/Hypnovel), a 100 µL mixture of PBS containing MagO2MB-
RB / MagO2MB-5FU (MB = 1.6 x 10
8, [RB] = 350 µM and [5-FU] = 700 µM) was administered by 
tail vein injection to Groups 2 & 3 while Group 1 received vehicle only. For Group 2, ultrasound 
(frequency =1 MHz, ultrasound power density = 3.5 Wcm-2 ISATP; spatial average temporal peak, 
corresponding to a free field peak to peak pressure of 0.85 MPa, duty cycle = 30% and pulse 
repetition frequency = 100 Hz) was directed to the tumour region (determined using prior 
bioluminescent imaging) via the abdomen for 3.5 min during and after injection (3.5 min total). 
For Group 3, in addition to ultrasound using the above parameters, a stack of permanent 
magnet discs (arranged to deliver the optimal magnetic force to the tumour region) [24] was 
directed to the tumour region (again via the abdomen) for 3.5 min during and after injection (3.5 
min total), resulting in an approximate magnetic field at the tumour of 0.10 T and gradient 14.9 T 
m-1. Treatments using the above conditions were repeated on days 20 and 21 with animals 
sacrificed on day 28. Tumours were then surgically excised and tumour volumes determined by 
direct measurement.   
2.7 Determination of apoptotic marker expression in tumours post treatment: Following 
the determination of tumour volume a single cell suspension was prepared from the excised 
tumours. This involved homogenising the tumour tissue in 4 % FCS in RPMI 160 uL (30 mg/ml) 
collagenase type II, 50 µL (2 µg/ml) DNAse and stirring for 15 min at room temperature. A 
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further 160µL of collagenase II was subsequently added and the contents stirred for a further 15 
min.  The mixture was filtered through a 100 µm filter, centrifuged at 1700 rpm for 5 min and re-
suspended in 1mL of Red Cell Lysis Buffer (RCLB) for 10 min. RCLB was neutralised by adding 
media containing FCS and cells were recovered by centrifuging at 1700 rpm. The pellet was 
washed twice with PBS, centrifuged and re-suspended in 700 µL PBS buffer.  For BAX 
expression, 300 µL of single cell suspension in staining buffer was permeabilised using BD 
permeablisation buffer (BD Biosciences UK). Permeabilised cells were re-suspended in 300 µL 
of staining buffer containing BAX antibody (Cell Signalling Technology, D2E11) (10 μg/ml) and 
incubated for 30 min at room temperature. The cells were washed in ice cold PBS and the cell 
pellet was re-suspended in FITC secondary antibody (Abcam, ab6717-1) for 1 hour.  Cells were 
washed three times by centrifugation at 400 RCF for 5 min in ice cold PBS, re-suspended in 650 
µL of PBS buffer nd analysed by flow cytometry. For active caspase expression, the Pan 
Caspase NIR probe kit (Vergent Bioscience) was used according to the manufacturer’s 
instructions. The kit utilizes the caspase family inhibitor VAD-FMK conjugated to a near IR dye 
(780-VAD-FMK) as a marker that irreversibly binds to activated caspases in apoptotic cells. 
Essentially, 300 µL of tumour single cell suspension diluted in staining buffer was centrifuged, 
the pellet re-suspended in 300 µL of 1XCAS-MAP NIR probe and incubated at room 
temperature in the dark for 1 hour. Cells were washed three times by centrifugation at 400 RCF 
for 5 min in ice cold PBS and re-suspended in 650 µL of staining buffer and analysed by flow 
cytometry. qRT-PCR was used to investigate the expression of TMBIM1 in tumours as 
previously described [6]. Briefly, RNA was extracted from microdissected slides using the 
RecoverAll Kit (Life Technologies, Paisley, UK). cDNA synthesis was carried out using the 
Superscript III First Strand cDNA synthesis kit (Life Technologies, Paisley, UK) using the 
reverse primer of each of TMBIM1 (transmembrane BAX inhibitor motif containing 1) and the 
two housekeeping genes;18S rRNA and b-actin. qRT-PCR was carried out using the SYBR 
Green kit on the CFX96 instrument (BioRad, UK). The qRT-PCR cycle was as follows: 95 C for 
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3 min, 95 C for 10 s, 60 C for 45 s for 40 cycles. For analysis, the geometric mean of 18S rRNA 
and b-actin was taken as the single housekeeping value. Statistical comparison between the 
groups was carried out using two-way ANOVA with Bonferroni post-hoc analysis. The primers 
used to investigate the TMBIM1 expression are shown in the table below. 
Primer Sequence 
TMBIM1  Forward CATCACTGCGGTGGTATCCA 
TMBIM1_Reverse GTATTGGAAGTAGAGCACAATGCTAGT 
β-Actin Forward CGTGGGCCGCCCTAGGCACCA 
β-Actin Reverse TTGGCCTTAGGGTTCAGGGGGG 
18SrRNA_Forward TGACTCAACACGGGAAACC 
18SrRNA_Reverse TCGCTCCACCAACTAAGAAC 
 
2.8 Toxicity determination of MagO2MB-5FU and MagO2MB-RB conjugates: Healthy MF1 
mice (8 weeks old) were randomly distributed into four groups (n=10). Group 1 received no 
treatment; Groups 2 & 3 received a tail vein injection (100 µL) of 5-FU (115 mM) or RB (1.03 
mM) respectively and Group 4 received a tail vein injection (100 µL) containing a suspension of   
MagO2MB-RB / MagO2MB-5FU ([MB] = 2.3 x 10
8, [RB] = 570 ± 15 µM, and [5FU] = 503 ± 7 µM] 
on Day 1 and Day 8. Pre-treatment tail vein bleeds (0.10 mL) were collected in lithium 
heparinised tubes on Day 0 with the post-treatment bleeds taken in a similar manner on Day 15. 
Blood samples were sent to CTDS Ltd (Leeds, UK) for whole blood and plasma biochemical 
analysis. Urea, alanine aminotransferase (ALT), red blood cell (RBC), haemoglobin (Hb), 
haematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), 
mean corpuscular haemoglobin concentration (MCHC), platelet, white blood cell, neutrophil and 
lymphocyte levels were determined using accredited protocols. Following the day 15 bleed, 
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mice were then sacrificed and the liver and kidneys were surgically excised and placed in a 
formalin free tissue fixative solution (Sigma-Aldrich) for 24 hours. It should be noted that the 
liver was chosen in these studies because it has been shown that MB are removed from 
circulation by that organ following intravenous administration. The tissue was then placed in an 
automated Leica TP1020 tissue processor and passed between increasing concentrations of 
ethanol followed by xylene and paraffin wax 24 hours later. The wax embedded tissue samples 
were placed in moulds containing paraffin wax. Once the wax blocks had solidified, 5 µm 
sections were cut, placed on a glass slide and stained with haematoxylin and eosin (H&E) using 
an automated staining protocol. In some cases, additional stains (i.e. reticulin, Masson’s 
trichrome, Perl’s Prussian blue stain) were used if required. The stained sections were reviewed 
histologically by pathologists with expertise in liver and renal pathology. Liver architecture was 
initially assessed to establish if there was significant remodelling or fibrosis. The various liver 
compartments were subsequently examined for pathological changes. Portal tract and lobular 
inflammation grading was adapted from the Ishak (modified HAI) system [25]. Portal tract 
inflammation was graded numerically from 1 (none) to severe, affecting all portal tracts (5). 
Lobular inflammation was assessed at x10 magnification and graded as 1 (none) to 4 (severe, 
typically averaging >10 foci per x10 field). Fatty liver disease grading, referred to as 
steatosis/steatohepatitis, was undertaken based on parameters assessed in the NAFLD activity 
score [26].  In short, steatosis was graded based on a visual estimate of the percentage of liver 
cells affected as 1 = none or less than 5%; 2 = mild, (5- 33%); 3 = moderate (34 – 66%) and 4 = 
severe (greater than 67%). Kidney analysis was undertaken following a similar approach 
assessing the glomerular cellularity, glomerular basement membrane, tubular vacuolation, 
interstitial inflammation, interstitial fibrosis, vessel integrity and the collecting system. Statistical 
analysis was undertaken using a student’s t-test where the MagO2MB-RB / MagO2MB-5FU 
group was compared directly with the 5-FU, RB and untreated groups.  
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 3.0 Results and Discussion: Magnetic microbubbles (MagMBs) were prepared by sonication 
of DBPC, DSPE-PEG(2000) and DSPE-PEG(2000)-biotin lipids in the presence of PFB gas and 
superparamagnetic iron oxide nanoparticles (NPs). The magnetic nanoparticle formulation 
comprised an iron oxide core with a lipid coating to facilitate incorporation of the magnetic 
nanoparticles into the MB shell. The PFB containing MagMBs (MagPFBMBs) produced had an 
average diameter of 1 - 2 μm with a concentration of approximately 1 x 109 MB/mL as 
determined by analysis of optical microscopy images (Figure 1).  
 
Figure 1 (a) Photomicrograph taken with a 40x objective lens of MagMBs after centrifugation 
(300 RCF, 5 min) and after dilution (1:20) in PBS. Scale bar is 20 µm. (b) Size distribution of 
MagMBs obtained from analysis of 30 optical microscope images. White boxes on the left 
represent microbubbles detected by the image analysis software but smaller than 450 nm, the 
optical resolution of the system. 
The iron content of the MagPFBMBs was also determined using atomic absorption 
spectroscopy and revealed the MBs contained 0.286 mg/109 MBs total iron content. Following 
isolation of the MagPFBMBs by centrifugation and surface coating with avidin, biotinylated Rose 
Bengal and biotinylated 5-FU were added to separate batches of the MagPFBMBs to generate 
Rose Bengal loaded MagPFBMBs (MagPFBMB-RB) and 5-FU loaded MagPFBMBs 
(MagPFBMB-5FU) respectively. The PFB core gas was then exchanged with oxygen by 
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sparging with pure oxygen gas for 2 min generating the MagO2MB-RB and MagO2MB-5FU 
conjugates (Scheme 1).   
 
Scheme 1 Schematic representation of the MagO2MB-5FU and MagO2MB-RB conjugates. 
To determine the magnetic response of the MB platform, suspensions of MagMBs (1 
mL) were placed in a syringe and pumped through a flow chamber (0.6 mL/min) with a fixed 
magnet (0.46 T) positioned on the underside of the flow chamber during the course of the 
experiment. A control study was also performed in the absence of a fixed magnet but under 
otherwise identical conditions. The number of MBs retained in the flow cell at the end of each 
experiment were counted and the results are shown in Figure 2. A significant increase in the 
number of MBs (p<0.01) was observed when the fixed magnet was present indicating the ability 
of the MagMBs to be retained against flow using an external magnetic field. Blood flow rates 
within the human body vary considerably depending on vessel type and size with blood leaving 
MagO2MB-RB
MagO2MB-5FU
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the aorta (2400 cm min-1) at a flow rate approximately 3 orders of magnitude greater than in 
capillaries (1.8 cm min-1) [27]. In tumours, the increased viscous and geometrical resistance 
presented by the vasculature can compromise its blood flow, meaning the average velocity of 
blood in tumour vessels can be an order of magnitude lower than in normal vessels [28]. 
Therefore, the flow rate used in the current study was towards the upper limit of rates chosen to 
study tumour perfusing resistivity which suggests that magnetic targeting may be effective in 
helping retain the MBs in the tumour vasculature and allowing a greater proportion to be 
destroyed in an applied acoustic field. 
 
Figure 2   Plot of MBs retained after injection through a flow-cell in the presence and absence 
of a fixed magnet.  
 In order to retain a useful proportion (10%) of injected microbubbles at these blood flow 
rates, an estimated magnetic field gradient of 0.15 T/m would provide sufficient force to capture 
superparamagnetic particles flowing the capillary vessels [29]. When considering the possible 
translation of such technology to the clinic, both transabdominal and endoscopic sources are 
viable methods for the delivery of magnetic fields to the pancreas. In the context of the above 
capillary flow rates, optimized permanent magnet designs with a volume of 1.02 cm3 [20] would 
16 
 
be capable of targeting a tumour through the duodenal wall as part of an endoscopic probe, 
where the approximate distance to the head of the pancreas is in the region of 10 mm. In the 
case of transabdominal delivery, where the distances are more variable depending on the 
patient’s body to mass index (BMI), the optimised permanent magnet volume would be in the 
region of 1.66 cm3, based on a distance of 50 mm from the outside of the abdomen to the 
pancreas. Even at flow rates 5 times higher than the capillary flow rate used above, the 
estimated field gradient to retain the same fraction of MBs would be 2.48 T/m, requiring 
permanent magnet volumes in the region of 1.5 cm3 for an endoscopic device, which is readily 
achievable [30]. Given endoscopic ultrasound (EUS) analysis is a common diagnostic tool used 
in staging pancreatic cancer, a EUS device configured to deliver both magnetic and ultrasonic 
fields is one possibility for the translation of this technology to clinic. 
 In a previous study, we demonstrated the benefit of combining Rose Bengal mediated 
SDT and 5-FU treatment, delivered using a non-magnetic O2MB platform, for the treatment of 
pancreatic cancer [6]. In the current study, we were keen to ensure that the presence of redox 
active Fe(II) and Fe(III) in the MB shell, would not hamper the effectiveness of SDT or 5-FU 
treatment. Therefore, the next step was to determine the toxicity of the combined treatment in a 
panel of pancreatic cancer cell lines. Human pancreatic BxPC-3, MiaPaCa-2 and Panc-01 cells 
were chosen as targets in addition to the T110299 cell line [31]. The latter was isolated from a 
primary pancreatic tumour in the KPC model (Ptf1a-Cre; LSL-KrasG12D and Ptf1aCre; LSL-
KrasG12D; LSL-Trp53fl/R172H mice, respectively, that were back-crossed on a C57BL/6 
background). The cells were seeded in 96 well plates and treated with a suspension of either 
MagO2MB-5FU, MagO2MB-RB or combined MagO2MB-5FU / MagO2MB-RB treatment in the 
presence of ultrasound. Untreated cells and cells treated with ultrasound only were used as 
controls. 
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Figure 3 Plot of % cell viability for (a) BxPC-3 (b) T110299 (c) MiaPaCa-2 and (d) Panc-01 after 
treatment with (i) untreated, (ii) ultrasound only (iii) MagO2MB-5FU only (iv) MagO2MB-RB only, 
 
 
(a)  
(b)  
(c)  (d)  
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(v) combined MagO2MB-RB and MagO2MB-5FU and (vi) combined MagO2MB-RB and 
MagO2MB-5FU plus ultrasound. *** p <0.001 for (vi) compared to either (ii), (iii), (iv), or (v). 
The results are shown in Figure 3 and reveal a significant reduction (p<0.001) in cell viability for 
all cell lines that received combined SDT and 5-FU treatment with reductions greater than 50% 
relative to the untreated cells. In contrast, both the MagO2MB-5FU and MagO2MB-RB 
formulations demonstrated only minor reductions (< 10%) in the absence of ultrasound 
treatment meaning it was possible to control the generation of cytotoxicity using the ultrasound 
stimulus. Therefore, these results suggest that application of ultrasound not only disrupts the 
MBs releasing the encapsulated O2 gas and the attached Rose Bengal / 5-FU into the 
extracellular medium but also activates Rose Bengal leading to ROS generation and the 
observed cytotoxic effect [32] It is also possible that application of the ultrasound could be 
enhancing the action of 5-FU by means of sonoporation..  Indeed, it has been shown that this 
strategy can be employed to enhance the action of cancer chemotherapeutics by affording 
transient intracellular access of the drug via sonoporation [33]. 
While the in vitro cytotoxicity of the combined 5-FU / SDT treatment was encouraging, in 
vivo experiments are essential to identify the benefit of magnetic targeting. To this end, 
orthotopic human xenograft BxPC-3-Luc pancreatic tumours were established in SCID mice. 
Nineteen days following implantation the mice were randomly distributed into three groups 
(n=4). Group 1 received no treatment; Group 2 received a MagO2MB-5FU / MagO2MB-RB 
suspension administered intravenously with the tumour region exposed to low-intensity 
ultrasound during and following injection for a total exposure of 3.5 min. Group 3 also received 
an IV injection of the MagO2MB-5FU / MagO2MB-RB suspension but in addition to ultrasound 
treatment, a permanent magnet was also directed at the tumour during ultrasound treatment 
(3.5 min). Treatments were repeated on days 20 and 21 with the mice sacrificed on day 28 [34]. 
This treatment schedule was determined on the basis of a previous pilot study where multiple 
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treatments in close succession were shown to be beneficial over a single treatment. In addition, 
as our primary goal is to use this technology as a neo-adjuvant treatment to downstage tumours 
in advance of surgery, aggressive treatment of the tumours with three successive 
administrations was the preferred choice and as the technology is targeted, significantly lower 
concentrations of RB and 5-FU are used compared to standard systemic administration. Once 
the mice were sacrificed, the tumours were surgically excised and volumes determined with the 
results for the three groups shown in Figure 4. 
 
Figure 4 (a) Photographs of orthotopic BxPC-3 Luc tumours removed from SCID mice 28 days 
following implantation after (i) no treatment (top), (ii) treatment with combined MagO2MB-RB 
and MagO2MB-FU plus ultrasound (middle) or (iii) treatment with MagO2MB-RB and MagO2MB-
FU plus ultrasound and magnet (bottom). Treatments were administered on day(s) 19, 20 and 
21. (b) Plot of % change in tumour volume relative to untreated for mice treated with (ii) or (iii) 
(a) 
(b) 
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above. * p < 0.05 for (iii) compared to (i). A one-way ANOVA, post-Hoc test showed the same 
significance as above. 
A statistically significant reduction in tumour volume of 48.3% (p<0.05) was observed for Group 
3 relative to control Group 1, while for Group 2 an obvious downward trend in tumour volume 
(27.9%) was detected although this was not found to be statistically significant. This 
improvement in efficacy in the presence of a magnetic field could be due to more MBs being 
retained in the tumour microenvironment, so that ultrasound exposure can enable enhanced 
deposition of MB payloads and subsequent activation of the sensitiser. Although the latter would 
require verification by further experimentation, our suggestion is corroborated by the 
observation that, activated caspase and BAX protein levels were both significantly elevated in 
tumours harvested from Group 3, when compared to expression of those proteins in tumours 
from either of the other 2 groups (p<0.05) (Figure 5). 
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Figure 5 (a) Plot showing presence of active caspase  in single cell suspensions of tumours 
removed from SCID mice 38 days following implantation after treatment with (i) no treatment 
(left), (ii) treatment with combined MagO2MB-RB and MagO2MB-5FU plus ultrasound (middle) 
or (iii) treatment with MagO2MB-RB and MagO2MB-5FU plus ultrasound and magnet (right). 
Fluorescence indicates caspase activity which is reflective of apoptosis and was determined 
using the Pan Caspase probe (Pan Caspase NIR from Vergent Bioscience) via flow cytometry. 
Treatments were administered on Days 19, 20 and 21. (b) BAX protein expression of the same 
single cell suspensions via flow cytometry. *p < 0.05 for (iii) compared to (i). (c) Relative 
expression of TMBIM1 in untreated control tumours and those receiving combined treatment. 
***p<0.001. 
  Increases in activated caspase and BAX protein levels are indicative of increased 
apoptosis and consistent with the increased treatment efficacy observed for Group 3.   Although 
BAX and caspase were not significantly increased in group 2, a trend in tumour size reduction 
was observed for this group (Figure 4).  In addition, previous studies have shown that ectopic 
BxPC-3 tumours receiving the combined treatment in the absence of a magnetic field resulted in 
decreased tumour size and expressed markers for increased apoptosis [6].  Although significant 
differences exist in the manner in which this and the previous study were performed both from 
the perspective of the model type (orthotopic vs. ectopic) and that of the dosing regimen 
(multiple vs. single), it was felt that the reduction ‘trend’ observed in group 2 in the current study 
(Fig.4) warranted further consideration. To this end, we have been able to use qRT-PCR 
analysis to demonstrate that TMBIM1 (encoding transmembrane BAX inhibitor motif containing 
1) was significantly downregulated in tumours receiving the combined treatment in the absence 
of a magnetic field (Figure 5). Since TMBIM1 is an inhibitor of BAX [35], its down regulation in 
these tumours could lead to enhanced BAX-mediated apoptosis without an observable change 
in BAX concentration. However, the authors do realise that the data presented in figures 4 and 5 
were derived from tumours removed at a specific time point (9 days) following treatment and 
these data may differ if longer or shorter time-points were chosen. Continuing studies will 
include a more in-depth examination of gene expression at various time points in order to more 
22 
 
clearly elucidate the interplay between both of these genes and their role in treatment-induced 
apoptosis.    
It was also found during the above studies that animals receiving the magnetically-
responsive platform did not suffer any overt adverse effects and no significant change in body 
weight was observed over the course of the experiment (Figure 6a). To investigate the aspect of 
safety further, a more detailed toxicology study was undertaken. This involved administering the 
MagO2MB-5FU / MagO2MB-RB suspension to 10 healthy non-tumour bearing MF1 mice by tail 
vein injection on Days 0 and 8. Similar experiments were undertaken involving MF1 mice 
treated with 5-FU or Rose Bengal alone at concentrations higher than those present on the 
MagMBs to reflect clinical doses, while untreated animals served as a control group. Blood 
samples were harvested from each group of animals on Day 15 and analysed for a range of key 
biochemical markers (Figure 6b). No major differences in profile were observed between the 
MagO2MB-5FU / MagO2MB-RB group and the other groups that would raise any concern 
regarding toxicity of the combined MB-based treatment. Indeed ALT activity, which is a measure 
of liver function, was lower in the MagO2MB-5FU / MagO2MB-RB group compared to the other 
groups. While there was an increase in platelet and lymphocyte levels for the MagO2MB-5FU / 
MagO2MB-RB group relative to the untreated group, levels were also raised in 5-FU and Rose 
Bengal treated animals and the differences between these groups were not significant.  
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Figure 6 (a) Average body weight of mice recorded following treatment with vehicle only 
(triangles), a suspension of MagO2MB-RB / MagO2MB-5FU + ultrasound (squares), or a 
suspension of MagO2MB-RB / MagO2MB-5FU + ultrasound + magnet (circles). (b) Whole blood 
and serum biochemistry analysis from healthy MF1 mice (i) untreated control, or treated with (ii) 
a suspension of MagO2MB-RB / MagO2MB-5FU, (iii) 5-FU alone, or (iv) RB alone. 
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Similarly, there was evidence of mild neutropenia in the three treatment groups relative 
to the untreated group, but again the difference between the MagO2MB-5FU / MagO2MB-RB 
group and the 5-FU and RB groups was not significant. Furthermore, histological analysis of 
liver and kidney sections removed post-mortem on Day 16 also revealed no significant changes 
between the MagO2MB-5FU / MagO2MB-RB group and the 5-FU or RB treated groups (Figure 
7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Scoring for sections of (a) liver and (b) kidney following (i) no treatment, or treatment 
with (ii) 5-FU alone, (iii) RB alone, or (iv) a suspension of MagO2MB-RB / MagO2MB-5FU 
conjugates. Portal inflammation scored 1-5 while all other parameters were scored from 1-4. In 
each case a score of 1 = normal.  
(a)  
(b)  
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There was evidence of a slight increase in liver steatosis score for the MagO2MB-5FU / 
MagO2MB-RB group but this was not significant when compared to the 5-FU or RB groups. 
Liver steatosis, also known as fatty liver disease, is normally a consequence of dietary or 
lifestyle habits but can also be influenced by certain chemotherapeutic drugs including 
antimetabolites [36]. The slight increase in score for the MagO2MB-5FU / MagO2MB-RB group 
relative to 5-FU or RB may be due to the uptake and metabolism of the lipid component of the 
MBs and on that basis is likely a transient change of limited clinical significance. Analysis of 
kidney sections showed slightly raised levels of glomerular cellularity and tubular vacuolation for 
the MagO2MB-5FU / MagO2MB-RB group, but again these levels were also raised in the 5-FU 
and RB groups and the differences were non-significant. Some of the tubular vacuolation may 
have been artefactual, possibly fixation related, as it was observed in both treated and untreated 
groups. It must be stressed, however, that any effect observed in the liver or kidney histology 
analysis was deemed to be mild and in no case did the mean score exceed 2. Collectively, 
these results indicate the potential of O2MagMBs as a safe and effective platform for the 
delivery of combined antimetabolite and SDT treatment of pancreatic cancer. 
 
 
 
 
 
Figure 8 Representative H&E stained microscope images of liver (top) and kidney (bottom) 
sections taken from animals sacrificed on day 15 following treatment with a suspension of 
MagO2MB-RB / MagO2MB-5FU (right) or untreated (left). 
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4.0 Conclusions: Magnetically responsive MBs were successfully prepared and shown to be 
retained at a target site in the presence of an externally applied magnetic field. When decorated 
with the sensitiser Rose Bengal and the antimetabolite 5-FU, the MagO2MB conjugates 
produced reductions of greater than 50% in the viability of four pancreatic cancer cell lines upon 
exposure to relatively low intensity ultrasound. The combined application of external magnetic 
and ultrasound fields during IV delivery of the MagO2MB conjugates resulted in a 48.3% 
reduction in orthotopic pancreatic tumour volumes 9 days after treatment relative to the control 
group, while the application of ultrasound alone resulted in a reduction of only 27.9%. In 
addition, a significant increase in apoptosis was observed in tumours that were treated with the 
MagMB conjugates and exposed to both magnetic and ultrasonic fields when compared to the 
ultrasound alone or untreated groups. These results highlight the potential of using a 
combination of magnetic and ultrasonic fields to retain and disrupt MBs in the tumour 
vasculature. The results also confirm the effectiveness of combined sonodynamic / 
antimetabolite therapy delivered using the MagO2MB platform as a safe, highly targeted and 
efficacious treatment for pancreatic cancer.  
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